Francis Impens
The Impens lab executes high-risk high-reward projects that combine proteomics and infection biology expertise to gain fundamental knowledge about host-bacteria interactions and identify novel targets for antibacterial therapy. A major research axis of the lab is immunopeptidomics for the identification of antigenic peptides. In the BAXERNA project, the group will further improve its immunopeptidomics platform to identify novel antigens for M. tuberculosis, M. ulcerans, and A. baumannii.
Lennart Martens
The CompOmics group, led by Prof. Lennart Martens, are world leaders in the development of machine learning-based tools to extract information from mass spectrometry-based proteomics and metabolomics data. They have developed the most performant immunopeptide identification software to date (MS²Rescore), which boosts immunopeptide recovery by 35% compared to the state of the art. In the BAXERNA project, the group will further improve its immunopeptidomics analytics workflow to identify novel antigens for M. tuberculosis, M. ulcerans, and A. baumannii.
Charles Van der Henst &
Alexandra Maure
The Van der Henst lab are experts on the WHO/CDC priority pathogen Acinetobacter baumannii. The lab performs both mechanistic and drug discovery studies on these bacteria and has characterized an extensive, validated collection of modern and clinically relevant A. baumannii isolates. In the BAXERNA project, they will leverage this collection together with their expertise in host-pathogen interactions to identify the most conserved antigens among virulent A. baumannii strains.
Francis Impens
The Impens lab executes high-risk high-reward projects that combine proteomics and infection biology expertise to gain fundamental knowledge about host-bacteria interactions and identify novel targets for antibacterial therapy. A major research axis of the lab is immunopeptidomics for the identification of antigenic peptides. In the BAXERNA project, the group will further improve its immunopeptidomics platform to identify novel antigens for M. tuberculosis, M. ulcerans, and A. baumannii.
Lennart Martens
The CompOmics group, led by Prof. Lennart Martens, are world leaders in the development of machine learning-based tools to extract information from mass spectrometry-based proteomics and metabolomics data. They have developed the most performant immunopeptide identification software to date (MS²Rescore), which boosts immunopeptide recovery by 35% compared to the state of the art. In the BAXERNA project, the group will further improve its immunopeptidomics analytics workflow to identify novel antigens for M. tuberculosis, M. ulcerans, and A. baumannii.
Charles Van der Henst &
Alexandra Maure
The Van der Henst lab are experts on the WHO/CDC priority pathogen Acinetobacter baumannii. The lab performs both mechanistic and drug discovery studies on these bacteria and has characterized an extensive, validated collection of modern and clinically relevant A. baumannii isolates. In the BAXERNA project, they will leverage this collection together with their expertise in host-pathogen interactions to identify the most conserved antigens among virulent A. baumannii strains.